Michael J. Tomsicek

2019 - CRISPR Therapeutics AG

In 2019, Michael J. Tomsicek earned a total compensation of $4M as Chief Financial Officer at CRISPR Therapeutics AG, a 79% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$228,665
Option Awards$1,948,673
Salary$394,250
Stock Awards$1,462,600
Other$9,800
Total$4,043,988

Tomsicek received $1.9M in option awards, accounting for 48% of the total pay in 2019.

Tomsicek also received $228.7K in non-equity incentive plan, $394.3K in salary, $1.5M in stock awards and $9.8K in other compensation.

Rankings

In 2019, Michael J. Tomsicek's compensation ranked 2,935th out of 13,971 executives tracked by ExecPay. In other words, Tomsicek earned more than 79.0% of executives.

ClassificationRankingPercentile
All
2,935
out of 13,971
79th
Division
Manufacturing
1,059
out of 5,701
81st
Major group
Chemicals And Allied Products
354
out of 2,200
84th
Industry group
Drugs
289
out of 1,886
85th
Industry
Biological Products, Except Diagnostic Substances
68
out of 389
83rd
Source: SEC filing on April 24, 2020.

Tomsicek's colleagues

We found four more compensation records of executives who worked with Michael J. Tomsicek at CRISPR Therapeutics AG in 2019.

2019

Samarth Kulkarni

CRISPR Therapeutics AG

Chief Executive Officer

2019

Lawrence Klein

CRISPR Therapeutics AG

Chief Operating Officer

2019

Tony Ho

CRISPR Therapeutics AG

EVP, Research and Development

2019

James Kasinger

CRISPR Therapeutics AG

General Counsel

News

You may also like